论文部分内容阅读
目的探讨培美曲塞联合顺铂与多西他赛联合顺铂一线治疗晚期老年肺腺癌的临床疗效。方法符合入组标准的72例晚期肺腺癌患者随机分为两组,每组36例。PEM组以培美曲塞联合顺铂化疗,DXT组以多西他赛联合顺铂化疗。结果所有患者均完成2个以上诊疗周期化疗,两组有效率、疾病控制率、中位生存期、中位无进展生存期差异无统计学意义(P>0.05)。PEM组Ⅲ-Ⅳ级毒性反应WBC、PLT减少及乏力、恶心呕吐的发生率低于DXT组(P<0.05)。结论培美曲塞联合顺铂与多西他赛联合顺铂一线治疗老年肺腺癌临床疗效相当,但培美曲塞联合顺铂毒副反应发生率低。
Objective To investigate the clinical efficacy of pemetrexed combined with cisplatin and docetaxel combined with cisplatin in the treatment of advanced lung adenocarcinoma of the elderly. Methods A total of 72 patients with advanced lung adenocarcinoma who met the inclusion criteria were randomly divided into two groups of 36 patients. PEM group with pemetrexed combined with cisplatin chemotherapy, DXT group docetaxel combined with cisplatin chemotherapy. Results All patients completed more than two cycles of chemotherapy. There was no significant difference in the effective rate, disease control rate, median survival, and median progression-free survival between the two groups (P> 0.05). PEM group Ⅲ-Ⅳ grade toxicity WBC, PLT decreased and fatigue, nausea and vomiting were lower than DXT group (P <0.05). Conclusions Pemetrexed combined with cisplatin and docetaxel plus cisplatin in the first-line treatment of elderly patients with lung adenocarcinoma have similar clinical efficacy, but the incidence of pemetrexed combined with cisplatin is low.